首页> 外文期刊>Journal of neuro-oncology. >Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.
【24h】

Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.

机译:垂体腺瘤中的端粒酶活性:端粒酶表达在预测垂体腺瘤复发中的意义。

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical and histopathological evaluations are inadequate for assessing biological aggressiveness and regrowth potential in benign pituitary adenomas. To develop reliable and prognostically informative means of predicting behavior remains an intractable problem. Telomerase, a reverse transcriptase that extends telomere length, may facilitate tumorigenesis and tumor immortality. In the present study, we investigated the telomerase activity of pituitary adenomas, and attempted to assess the value of telomerase expression for predicting their clinical course. In total, 31 (30 patients) benign pituitary adenoma samples including 8 recurrent adenomas were studied. Telomerase expression was evaluated by polymerase chain reaction (PCR)-based telomeric repeat amplification protocol (TRAP) assay and telomerase activity levels were quantitated by improved PCR enzyme-linked immunosorbent assay (ELISA). The data were analyzed in relation to clinical course which was reviewed at 4-5.5 years (median follow-up time, 52.5 months) after surgery. The relative values of the telomerase expression for predicting the clinical course were compared with the MIB-1 antigen-based proliferative cell index (PCI) and p53 immunoreactivity which have recently been suggested to correlate with aggressive behavior in pituitary adenomas. Overall, telomerase expression was detected in 13% of the adenomas (4 tumor tissues, 3 patients). These adenomas comprised large, invasive, and functioning adenomas. The number of telomerase-positive adenomas was small; however, the PCI was higher in cases with telomerase expression (4 tumor tissues; mean, 4.2 +/- 2.4%) than in those without it (27 tumor tissues; 1.4 +/- 1.3%) (p = 0.01). One tumor with detectable telomerase expression, which did not undergo additional pharmacological or radiotherapeutic intervention after first surgery, recurred rapidly despite gross total surgical resection, although the PCI of both the primary and recurrent adenomas was not high. Detection of telomerase expression may represent an additional useful means of identifying aggressive behavior, complementing the histopathological evaluation of benign-appearing pituitary adenomas.
机译:临床和组织病理学评估不足以评估良性垂体腺瘤的生物学侵袭性和再生潜力。开发可靠的,可预测信息的行为预测方法仍然是一个棘手的问题。端粒酶是一种延长端粒长度的逆转录酶,可促进肿瘤发生和永生。在本研究中,我们调查了垂体腺瘤的端粒酶活性,并试图评估端粒酶表达对预测其临床进程的价值。总共研究了31例(30例患者)垂体良性腺瘤样本,包括8例复发性腺瘤。通过基于聚合酶链反应(PCR)的端粒重复扩增协议(TRAP)分析评估端粒酶表达,并通过改进的PCR酶联免疫吸附分析(ELISA)定量端粒酶活性水平。分析与临床病程相关的数据,并在手术后4-5.5年(平均随访时间52.5个月)进行回顾。将端粒酶表达的相对值用于预测临床病程,并将其与基于MIB-1抗原的增殖细胞指数(PCI)和p53免疫反应性进行了比较,最近发现这些信息与垂体腺瘤的侵袭行为相关。总体而言,在13%的腺瘤(4个肿瘤组织,3例患者)中检测到端粒酶表达。这些腺瘤包括大的,侵入性的和起作用的腺瘤。端粒酶阳性腺瘤的数量很少;然而,在有端粒酶表达的病例(4个肿瘤组织;平均为4.2 +/- 2.4%)中,PCI高于没有端粒酶的患者(27个肿瘤组织; 1.4 +/- 1.3%)(p = 0.01)。尽管原发性和复发性腺瘤的PCI均不高,但尽管进行了总的手术切除,但具有可检测到的端粒酶表达的肿瘤在首次手术后并未接受额外的药理或放疗干预,但仍迅速复发。端粒酶表达的检测可能代表鉴定侵略性行为的另一种有用手段,补充了良性垂体腺瘤的组织病理学评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号